Replies to post #10592 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi...

June 6, 9:30 AM ET
UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi says management's rhetoric indicates approval for generic Copaxone may come in time for 2015 patent expirations.

http://seekingalpha.com/currents/post/1068791